Heterogeneity of @entity855 -based chemotherapy response assay in XXXX --secondary publication.

@entity1 @entity2600 @entity0 @entity1311 @entity189 @entity20171 @entity1487 @entity14 @entity855
PURPOSE: @entity855 -based chemotherapy response assay ( @entity855 - @entity20171 ) is a well-documented and validated technology that can individualize chemotherapy for @entity1 with lung, stomach, or @entity0 . This study explored the feasibility of @entity855 - @entity20171 as a chemosensitivity test in @entity1 with @entity14 . MATERIALS AND METHODS: A total of 118 @entity1 who underwent surgical resection for @entity14 were analyzed for chemosensitivity to 6 anticancer drugs using @entity855 - @entity20171 . We calculated the cell death rate (CDR) by measuring intracellular @entity855 levels of drug-exposed cells and untreated controls. RESULTS: Interpretable results were available for 85.5% (118/138) of @entity1 . The mean coefficient of variation for triplicate @entity855 measurements was 9.2%. The highest CDR was observed in @entity2600 (34.0%) and the lowest CDR in etoposide (21.0%). @entity1311 had the broadest range of CDR (0-86.7%) and @entity1487 had the narrowest range of CDR (0-56.8%). The overall highest responsiveness was seen most prevalently in @entity2600 (24.7%, 23/93 @entity1 ). @entity2600 had the greatest responsiveness in @entity1 with well differentiated and moderately differentiated @entity189 . CONCLUSION: Our study suggests that @entity855 - @entity20171 could be used to identify @entity1 with @entity14 who might benefit from treatment with a specific chemotherapeutic agent.
